Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial

Eli Lilly said its experimental combination regimen showed greater weight loss than a high dose of its top-selling drug, tirzepatide, alone in a mid-stage trial on patients with obesity and Type 2 dia...

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。